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T
he endothelium, once considered a
mere selectively permeable barrier
between the bloodstream and the
outer vascular wall, is now recognized to
be a crucial homeostatic organ, funda-
mental for the regulation of the vascular
tone and structure. Indeed, endothelial
cells are able to synthesize and secrete a
broad spectrum of anti-atherosclerotic
substances, the most characterized of
which is nitric oxide (NO), a gas that
is generated from the metabolism of
L-arginine by endothelial NO synthase
(eNOS),constitutivelyexpressedinendo-
thelial cells (1). Under physiologic condi-
tions, endothelial stimulation induces the
production and release of NO, which dif-
fuses to surrounding tissue and cells and
exertsitscardiovascularprotectiveroleby
relaxing media-smooth muscle cells, pre-
venting leukocyte adhesion and migra-
tion into the arterial wall, muscle cell
proliferation,plateletadhesionandaggre-
gation,andadhesionmoleculeexpression
(1,2).Indiseaseconditions,includingthe
presence of cardiovascular risk factors,
the endothelium undergoes functional
and structural alterations, thus losing its
protective role and becoming a proath-
erosclerotic structure (1). In the earliest
stages,theprincipalendothelialalteration
ismerelyfunctionalandaddressedas“en-
dothelial dysfunction.” The fundamental
feature of this condition is the impaired
NObioavailability.Thiscanbetheconse-
quence of either a reduced production by
eNOSor,morefrequently,ofanincreased
breakdown by reactive oxygen species
(ROS)(1,2).Inthepresenceofimpaired
NO bioavailability, the endothelium
implements various physiological path-
waysintheattempttocompensateforNO
deﬁciency. For instance, endothelium-
dependent vasodilation is warranted,
although impaired, also in the presence
ofcardiovascularriskfactorsbythepro-
duction and release of endothelium-
derived vasodilators other than NO,
such as prostanoids and other endothe-
lium-derived hyperpolarizing factors.
Along with NO deﬁciency, a dysfunc-
tioning endothelium also becomes the
source of other substances and media-
tors that are detrimental to the arterial
wall, including endothelin-1, trombox-
ane A2, prostaglandin H2, and ROS (2).
The presence of endothelial dysfunc-
tion, whether primary or after cardiovas-
cular risk factors, has been implicated in
the pathogenesis of atherosclerosis and
thrombosis, both for the loss of its pro-
tective capability and for the induction
of proatherothrombotic mechanisms
(2,3).
Theregulationoftheendothelialpro-
cesses is largely vascular district–speciﬁc,
thusproducingdifferentresultsinvarious
organs and tissues. Within the same vas-
culardistrict,itvarieslargelyinrelationto
vesselsize,i.e.,largearteries(macrocircu-
lation) versus arterioles (microcircula-
tion). For this reason, the use of systemic
circulating markers of endothelial func-
tion is unreliable. Moreover, NO is a vol-
atile substance, with a very short half-life,
and therefore its moment-by-moment
quantiﬁcationinaspeciﬁcvascularareais
almostimpossible.Therefore,itsbioavail-
ability is usually evaluated in humans by
measuring the downstream effects,
namely the vasodilation induced by the
local stimulation of NO production by
speciﬁcexternalmechanicalandpharma-
cological stimuli, i.e., through vascular
reactivitytests(4).Inparticular,endothe-
lium-dependent relaxation has been eval-
uated by the use of either receptor-
operated (acetylcholine, bradykinin,
substance P), mechanical (increase in
shear stress), or mixed (dynamic exercise
and cold pressor test) stimuli and in dif-
ferentvascularbeds(4,5).Atthecoronary
level,endothelialfunctioncanbeassessed
in the macrocirculation by quantitative
angiography, evaluating the change in
coronary artery diameter after local infu-
sion of agonists (e.g., acetylcholine), and
in the microcirculation as changes in ﬂow
by intravascular ultrasound (4). This cen-
tral approach is potentially the one with
thehighestclinicalvalue,sinceitexplores
the vascular bed more often involved
by the atherosclerotic process and is re-
sponsible for cardiac events. However, its
invasiveness highly limits its applicability
(4). Therefore, several other techniques
have been developed to assess peripheral
circulation endothelial function. In par-
ticular, peripheral microcirculation can
be contemplatedly studied by venous
plethysmography to evaluate forearm
blood ﬂow changes to intra-arterial infu-
sion of various substances. This approach
is useful, since it facilitates the study of
mechanisms underlying endothelial dys-
function by administering endothelial
agonists and antagonists (4). However,
again, forearm blood ﬂow is still invasive
and requires brachial artery cannulation.
For this reason, in the last decade, ﬂow-
mediated dilation (FMD) of the brachial
artery has been widely used among re-
searchers. Indeed, although its reproduc-
ibility is limited, FMD has the advantage
of being completely noninvasive since it
usesultrasoundanalysisofbrachialartery
diameter after a local increase in shear
stress, induced by a 5-min forearm isch-
emia (4). However, it is noteworthy that
vascular responses obtained in different
vascular areas/districts and using differ-
ent stimuli and techniques are poorly
related (6). Considering this aspect and
the autocrine-paracrine nature of endo-
thelial physiology, extreme caution
should be taken in interpreting experi-
mental studies and mostly in consider-
ing data obtained in a vascular region as
indicative of endothelial function in
other areas.
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UNDERLYING DIABETES-
RELATED ENDOTHELIAL
DYSFUNCTION— Patients with di-
abetes invariably show an impairment of
endothelium-dependent vasodilation.
Thisispartlyduetothefrequentassociation
ofthediseasewithothercardiovascularrisk
factors, including hypertension, obesity,
anddyslipidemia.Moreoverdiabeticaswell
as obese patients usually consume a high-
calorie diet rich in macronutrients that
per se is able to induce vascular abnor-
malities. Indeed, protein (7), lipid (7),
andglucose(8)loadsareassociatedwitha
marked production in ROS, and high-fat
meals are associated with an impaired en-
dothelial-dependent vasodilation (9). A
crucial negative effect is particularly at-
tributable to high levels of circulating free
fatty acids, which are able to induce ROS
production and impair endothelial func-
tion (10). Mechanisms of endothelial
damageindiabetes,independentlyfrom
other cardiovascular risk factors, include
insulin resistance, hyperglycemia, and
low-grade systemic inﬂammation (11)
(Fig. 1).
A large amount of literature has been
published on the interaction between in-
sulin and NO system. It was shown that,
in normal subjects, insulin is able to in-
duce a dose-dependent increase in lower
limb blood ﬂow by reducing vascular re-
sistance in skeletal muscle (12), mainly
vasodilating the microcirculation (13).
This observed vasodilatory effect of insu-
lin is, at least partly, mediated by the en-
hanced production of NO both through
the activation of the insulin receptor sub-
strate-1/phosphoinositol 3-kinase/Akt
pathway (14) and increased expression of
eNOS (15). Interestingly, studies on
lower limb circulation showed that the
magnitude of vasodilation to insulin ap-
pears to be linked to the rate of insulin-
mediated glucose metabolism (16).
However,somecontroversiesexistonthis
topic, with other groups, including ours
(17), failing to detect a net direct effect of
insulin in inducing vasodilation. The rea-
sons for this could be related to the use of
different methodology used and different
analyzed vascular districts. Indeed, we
previously showed no net direct effect of
insulinonforearmmicrocirculation,buta
potentiating effect of insulin on acetyl-
choline-mediated vasodilation at this
level, possibly through a hyperpolarizing
effect on the endothelium (17).
However, insulin downstream path-
ways, whether through a direct interac-
tion with the eNOS/NO system or other
intracellular systems are implicated in the
regulation of vascular tone and reactivity,
since the presence of insulin resistance is
associated with the presence of endothe-
lial dysfunction, not only in diabetes and
obesity, but also in more clean models of
insulin resistance, such as polycystic
ovary syndrome (18).
ENDOTHELIAL FUNCTION
AND OTHER
CARDIOVASCULAR RISK
FACTORS— Endothelial dysfunc-
tion, detected as the presence of reduced
vasodilating response to endothelial stim-
uli,hasbeenobservedtobeassociatedwith
major cardiovascular risk factors, such as
aging, hyperhomocysteinemia, postmeno-
pause state, smoking, diabetes, hypercho-
lesterolemia, and hypertension (3).
The presence of multiple risk factors,
each contributing to the development of
impaired NO bioavailability by different
mechanisms, may be able to determine a
Figure 1—Principal mechanisms responsible for endothelial dysfunction in diabetes. NO is the principal anti-atherosclerotic endothelium-derived
mediator. It is formed from L-arginine by eNOS, being tetrahydrobiopterin (BH4), a crucial cofactor for the reaction. Endothelial dysfunction is
deﬁned by the presence of a reduced NO bioavailability. In the presence of diabetes, characterized by the existence of insulin resistance and
hyperglycemia,endothelialdysfunctionisduetobothreducedproduction(increasedcirculatinglevelsoftheeNOSendogenousinhibitorasymmetric
dimethylarginine [ADMA], decreased cellular levels of BH4 and decreased eNOS activation) and to an increased breakdown of NO by ROS. AGEs,
advanced aging end products; FFA, free fatty acids.
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function. Accordingly, endothelial func-
tioninthecoronarycirculationwasfound
to be inversely associated with the num-
ber of risk factors (19) and therefore with
theglobalcardiovascularrisk.Thiswasalso
conﬁrmed in the Framingham population,
in which an escalating inverse relationship
between endothelium-dependent relax-
ation, estimated by FMD, and the cardio-
vascular risk score, evaluated according
to tables from “Framingham risk score,”
was demonstrated (9).
Moreover, the relationship between
endothelial dysfunction and the presence
of cardiovascular risk factors may be two-
way. Indeed, recent data in postmeno-
pausal women suggest that endothelial
dysfunctionmaybeapredisposingfactor,
orananticipatingmarkerforthedevelop-
ment of hypertension (20) and diabetes
(21), thus being not only a consequence
or a collateral feature of risk factors, but
also a possible pathogenetic mechanism
for their onset.
ENDOTHELIAL FUNCTION
AND TARGET ORGAN
DAMAGE— Another important as-
pectconcernstheroleofendothelialfunc-
tion in the progression of atherosclerotic
lesions (Fig. 2). The importance of sub-
clinical and clinical target organ damage
is widely recognized and considered to
profoundly inﬂuence patients’ prognosis,
as emphasized recently by the 2007 Eu-
ropean Hypertension Guidelines, repre-
senting an intermediate stage in the
continuum of vascular disease eventually
leading to clinical events. The main rele-
vant organ damage includes vascular ath-
erosclerosis, detected by ultrasound
scanning; left ventricular hypertrophy,
assessed by electrocardiography or by
echocardiography; and renal damage, on
the basis of a reduced renal function
and/or the detection of elevated urinary
albumin excretion. These structural alter-
ations have been linked by experimental
evidence to the extent of endothelial dys-
function. In particular, increased intima-
media thickness of the common carotid
artery, which is a noninvasive marker of
atherosclerosis and a predictor of coro-
nary and cerebrovascular disease, was
demonstrated to be directly related to the
impairment of endothelial dysfunction in
theforearmmicrocirculationofhyperten-
sive patients (22) and in the brachial
macrocirculation of patients with coro-
nary atherosclerosis (23). The results of
these small studies have also been con-
ﬁrmed in the large cohort of the Cardio-
vascular Risk in Young Finns Study.
Indeed, the authors found that brachial
artery FMD was inversely associated with
intima-media thickness, also after adjust-
ing for age, sex, brachial vessel size, and
several risk variables (24). Finally,
Figure2—Schematicrepresentationofthecardiovascularcontinuumfromnormalphysiologiccondition(left)tothepresenceofcardiovascularrisk
factors, subclinical organ damage, and eventually cardiovascular, cerebrovascular, and renal events (right). The earliest vascular abnormality is
represented by endothelial dysfunction, which potentially precedes established cardiovascular risk factors, and tends to worsen in parallel with
aggravation of organ damage. TIA, transient ischemic attack.
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lial dysfunction of the conduit artery,
measured as brachial FMD, was indepen-
dently associated to carotid plaque in a
multi-ethnic population of elderly men
and women (25). Apart from large cere-
bro-afferent arteries, intracerebral micro-
circulatory endothelial dysfunction,
through the impairment of the blood-
brain barrier, cerebral autoregulation,
and prothrombotic changes, may also
play a role in the genesis of brain infarct
and in particular for the lacunar subtype.
This type of lesion is particularly frequent
in diabetic and hypertensive patients and
represents a risk for the development of
cognitive impairment and dementia. To
date, no speciﬁc study evaluating the re-
lationshipbetweenperipheralendothelial
function and brain lesions has been per-
formed. However, available data showed
increasedcirculatingmarkersofendothelial
activationanddamage,suchasintercellular
adhesion molecule-1, thrombomodulin,
tissue factor, and tissue factor pathway in-
hibitorinpatientswithcerebralsmallves-
sel disease (26).
Asigniﬁcantrelationshipbetweenen-
dothelial function and coronary athero-
sclerosis is also present. In patients with
coronary artery stenosis, a selective im-
pairment of endothelium-dependent va-
sodilation in coronary arteries was
demonstrated, not only in diseased ves-
sels, but also in nondiseased prestenotic
arterial segments or vessels, and in the
coronary microcirculation (3). In addi-
tion, in these patients, the endothelial
dysfunction is not only present centrally,
but also in the peripheral macro- and mi-
crocirculation (27). Notably, in patients
without angiographic evidence of coro-
nary atherosclerosis, the vasodilation to
intracoronary acetylcholine, index of en-
dothelial function, was found to be in-
versely related to the presence of
intramural plaques, as detected by Brun-
ner et al. (3). Moreover, in patients with
coronary artery disease, the presence of a
reduced coronary ﬂow reserve is associ-
atedwithamorepronouncedimpairment
in microvascular endothelial function
(28). These data are supported also by
longitudinal studies. In a group of pa-
tientswithhearttransplants,thepresence
of coronary endothelial dysfunction at
baseline was associated with a signiﬁcant
augmented risk of developing arteriolo-
sclerosisatthe1-yearfollow-up,aswellas
atherosclerotic lesions (29). Overall,
these results support the existence of a
linkbetweenendothelialdysfunctionand
the probability of developing structural
changes in the coronary and carotid
circulation.
It is well known that the increase in
left ventricular mass is able to indepen-
dently predict an increased risk for car-
diovascular disease, and regression of left
ventricular hypertrophy has a positive
prognostic impact (30). Available data
suggest that left ventricular hypertrophy
is associated with the presence of endo-
thelial dysfunction, particularly if a con-
centric geometry is present, and a direct
relationshipbetweenleftventricularmass
and the vasodilation to intrabrachial ace-
tylcholine was also described (21).
Targetorgandamage,otherthanlarge
arteries and heart, also includes impair-
ment in renal function. In particular, the
loss of albumin in urine is considered a
marker of impaired glomerular perme-
ability for plasma proteins and represents
an integrated marker of subclinical organ
damage, both in hypertension and in di-
abetes. Accordingly, existing data show
that the presence of microalbuminuria is
an independent predictor of renal events,
as well as cardiovascular mortality and
morbidity after adjustment for other con-
ventional cardiovascular risk factors (31).
Interestingly, in the LIFE trial, the levels
of albumin excretion at baseline were in-
dependent predictors of cardiovascular
outcomealsoinnondiabetichypertensive
patients with left ventricular hypertro-
phy, as well as for range of albuminuria
below the threshold to deﬁne microalbu-
minuria (32). The presence of reduced
endothelial function has been demon-
strated in diabetic patients with albumin-
uria compared with normoalbuminuric
diabetic patients, or healthy subjects, and
the level of albumin excretion is inversely
related to endothelium-dependent re-
sponse in several diabetic and nondiabetic
populations (32). Both microalbuminuria
and endothelial dysfunction are expres-
sions of an endothelial pathology; how-
ever, it is still uncertain whether they are
interrelated, or if the two phenomena are
caused in parallel by the cardiovascular
risk burden. Moreover, it is of note that
some studies failed to demonstrate a rela-
tionship between microalbuminuria and
endothelial dysfunction in hypertensive
patients, either in the peripheral macro-
circulation (33) and microcirculation
(34). Taken together, these data seem to
suggest either that no direct connection
between systemic endothelial function
and albumin excretion exists or that im-
paired endothelial function precedes the
development of microalbuminuria.
Another important renal parameter is
representedbyreducedrenalﬁltration.In
the presence of profoundly impaired re-
nal function, the high prevalence of tradi-
tional cardiovascular risk factors, as well
as the activation of other several mecha-
nisms reducing NO availability (35),
leads to marked endothelial dysfunction
(36), which is considered to be involved
in the accelerated atherosclerotic process,
andcardiovascularmorbidityandmortal-
ity,whichcharacterizepatientswithrenal
disease. Although, as noted, in advanced
renal disease, endothelial dysfunction is
constantly present and its degree is corre-
latedtothedegreeofglomerularﬁltration
rate decrease (36), the association be-
tween endothelial and renal function is
still uncertain in the presence of mild renal
insufﬁciency. Some scientiﬁc data support
the concept that hypertension-related en-
dothelial dysfunction, as detected also in
the peripheral microcirculation, may inde-
pendently favor the progressive reduction
in glomerular ﬁltration rate (37), although
this association was not conﬁrmed in
patients with severe coronary athero-
sclerosis (38).
ENDOTHELIAL FUNCTION
AND CLINICAL EVENTS— In re-
cent years, a large body of evidence has
been accumulating to support the hy-
pothesis that the presence of endothelial
dysfunction represents a major promoter
for atherosclerosis and thrombosis and is
an independent prognostic predictor for
the risk of future cardiovascular events in
severalgroupsofpatients(29,39)(Fig.3).
It is important to note that the vasodilat-
ing responses in different vascular zones
of the same subject are poorly related (6),
partly due to the different techniques and
stimuli used and partially because of the
highly speciﬁc regional regulation endo-
thelial physiology. Despite this, the pres-
ence of endothelial dysfunction is almost
invariably an independent predictor of
clinicaleventswhereverdetected.Indeed,
this prognostic role has been demon-
strated in peripheral and central circula-
tion, in microcirculation and large
arteries,andindependentlyfromtheused
endothelial stimulus (3,29,39). It should,
however, be emphasized that the total
number of clinical events so far investi-
gated is limited and does not allow deﬁ-
nition of the presence of endothelial
dysfunction as an independent risk factor
for cardiovascular events, since it could
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marker for global risk. Finally, some con-
ﬂictingstudiesshouldberemembered:In
ahigh-riskpopulation,thepresenceofre-
duced FMD showed an association to the
riskofcardiovasculareventsatfollow-up,
which was, however, not independent of
major cardiovascular risk factors (40),
andthecoronaryvasodilatingresponseto
acetylcholine may lose its predicting role
in patients referring for a coronary angio-
gram (41).
IS ENDOTHELIAL
DYSFUNCTION
RESOLVABLE?— Several nonphar-
macological and pharmacological ap-
proaches have been demonstrated to
improve or reverse endothelial dysfunc-
tion, although their effect is never selec-
tive and usually also target one or more
traditional cardiovascular risk factors.
Considering that oxidative stress is the
main pathophysiologic mechanism lead-
ing to impaired NO bioavailability and
endothelial dysfunction, immense atten-
tion has been drawn by antioxidant sub-
stances. Although in acute studies the use
of high-dose antioxidant vitamins is ex-
tremely effective in restoring normal en-
dothelial function, interventional studies
using oral administration of these sub-
stances (i.e., vitamin C and E) failed to
provide consistent data (42). However,
recently, other antioxidant compounds,
such as the ﬂavonoids contained in red
wine and chocolate, have been found to
ameliorate endothelial function in pe-
ripheral large arteries (43), although it is
difﬁcult to evaluate the importance of
their direct effect on the endothelium
from the beneﬁcial effect on blood pres-
sure and lipid proﬁle (43).
Among cardiovascular drugs, there is
a large variability as far as their effect on
endothelial function is concerned, de-
pending on their mechanism of action
and investigated vascular size and loca-
tion (29). In particular, classic antihyper-
tensive -blockers and diuretics are
invariably found to have little or no effect
on endothelium-dependent vasodilation
(29). An exception to this is represented
by newer -blockers. Nebivolol, indeed,
is able to induce vasodilation by a direct
effect on NO synthase and by its antioxi-
dant effect (29), and carvedilol was found
to suppress ROS generation and improve
endothelial dysfunction (44). However,
in general, newer drug classes are more
effective in the protection of the endothe-
lium. Speciﬁcally, calcium-channel
blockers have been consistently shown to
reverse impaired endothelium-depen-
dent vasodilation, mainly in the microcir-
culation, with conﬂicting results in the
brachial artery FMD (29). It is important
to note that the beneﬁcial effect of this
class of drug is strictly related to its well-
demonstrated antioxidant activity, which
improves NO bioavailability and goes be-
yond its antihypertensive effect. Indeed,
calcium-channel blockers are able to im-
prove endothelial function in normoten-
sive hypercholesterolemic patients as
well, without affecting blood pressure or
lipid levels (29). An entirely different sce-
nario characterizes the renin-angiotensin
system modulating drugs. In fact, both
ACE inhibitors and angiotensin receptor
blockers are characterized by several
pleiotropic effects, including antioxidant
and anti-inﬂammatory activities (45).
Several mechanisms inducing endothelial
dysfunction are certainly attributable to
angiotensinII,suchassuperoxideandva-
soconstrictingprostanoidproductionand
releaseofendothelin-1(45).Accordingly,
ACE inhibitors and angiotensin receptor
blockers have been shown to ameliorate
endothelium-dependent vasodilation in
several experimental settings, exploring
both coronary and peripheral large ar-
teries (29,45), but conﬂicting results
have been obtained in the microcircula-
tion (29).
Statins represent another important
cardiovascular drug class with proven
beneﬁcial effect in the primary and sec-
ondary prevention of cardiovascular
events, independently of their lipid-
lowering effect. Several ancillary proper-
ties of statins have been proposed to
explain their beneﬁcial excess, including
their endothelium-protective action. The
improvement of endothelial function by
statin treatment is related to its ability to
reduce LDL cholesterol levels and to par-
tially increase HDL cholesterol (46).
However, statins are able to improve en-
dothelial function, even in the absence of
any effect on lipid proﬁle (47), and in
populations with normal cholesterol
levels, but distinguished by endothelial
dysfunction, including smokers, hyper-
tensive, and diabetic patients. This ben-
eﬁcial action on endothelial function may
result as a consequence of various mech-
anisms, including the upregulation of
eNOS expression, the enhanced NO re-
lease, their antioxidant activity, and the
reduced expression and synthesis of en-
dothelin-1 (46).
Also, glitazones (insulin-sensitizing
agents used to treat patients with type 2
diabetes) have been found to have a pro-
tective and restoring effect on endothelial
function. In randomized studies per-
formed in diabetic patients, both rosigli-
tazone (48) and pioglitazone (49) were
able to improve endothelial function
compared with standard antidiabetic
drugs. Similar results were obtained also in
obesenondiabeticpatients(50).Theseben-
eﬁcial effects are the results of several pleio-
tropic actions of glitazones, including the
ability to reduce levels of asymmetric di-
methylarginine (51), a competitive inhibi-
tor of eNOS, to decrease ROS production
and inhibit vascular inﬂammation (52).
Figure 3—Meta-analysis of studies evaluating the association between coronary or peripheral
endothelial function and cardiovascular events. Adapted from Lerman and Zeiher (39).
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ENDOTHELIAL FUNCTION
CLINICALLY RELEVANT? — Given
these data, it is conceivable that the ther-
apeuticcorrectionofendothelialdysfunc-
tion may lead to an improvement of
prognosis in patients with cardiovascular
risk factors or cardiovascular disease.
However, scant data are available on this
topic, and most of the conclusions that
can be drawn are highly speculative.
There is, therefore, virtually no available
substance able to speciﬁcally target the
endothelium; moreover, the results of in-
terventional studies evaluating the effect
of cardiovascular drugs on endothelial
function vary, depending on the investi-
gated vascular zone and technique and
stimulus used.
To date, only one study (53) evalu-
ated the correctional effect of endothelial
dysfunction in terms of cardiovascular
risk events. A group of postmenopausal
hypertensive women with impaired en-
dothelial function, assessed by brachial
artery FMD, was treated with antihyper-
tensive drugs and followed up for 5
years. In the subgroup that experienced
amelioration of endothelial function
within 6 months from the onset of treat-
ment, the long-term outcome was found
signiﬁcantly better compared with the
subgroup without improvement in FMD,
withalowerrateofcardiovascularevents,
despite similar reduction in blood pres-
sure (53). These results support the con-
cept that the amelioration of endothelial
dysfunction is potentially a powerful tool
to reduce cardiovascular risk. Moreover,
it can be speculated that among cardio-
vasculardrugs,theoneswiththeancillary
property of improving endothelial func-
tion are possibly preferable in the treat-
ment of risk factors.
An argument against this may be a
derivative of evidence arising from con-
trolled clinical trials on the use of lipid-
lowering agents (54). Antihypertensive
drugs(55)haveclearlydemonstratedthat
thebeneﬁtisvirtuallyentirelyattributable
to the magnitude of cholesterol and low-
ering of blood pressure, respectively.
Moreover,ameta-analysisshowednodif-
ference among antihypertensive drugs in
improving patient prognosis (56), sug-
gestingthereductioninbloodpressureas
the only clinically important effect of
these drugs. It should be considered,
however, that the duration of controlled
clinicaltrialsisusually4–5years,andthis
may be insufﬁcient to detect additional
beneﬁt of some drug classes, especially in
low-risk patients. Another aspect to con-
sider is that of the deﬁnition of endothe-
lial function. The endothelium embodies
several activities contributing to vascular
protection beyond vasodilation, includ-
ing inhibition of platelet aggregation,
smoothmusclecellproliferation,andvas-
cular inﬂammation. The use of “endothe-
lial function” (which is deﬁned only on
vasoreactivity) as an ancillary target for
therapy, may in this sense not be com-
pletelycorrect,sinceitispossiblethatdrugs
improvingendothelium-dependentvasodi-
lation may potentially increase platelet ag-
gregation or inﬂammation, such as the case
for exogenous estrogen (57–59).
CONCLUSIONS— There is no doubt
thatthestructuralandfunctionalintegrity
of the endothelium is crucial to maintain
vascular homeostasis and prevent athero-
sclerosis. This, as mentioned, is docu-
mented by the increased risk of
developing target organ damage and car-
diovascular events in the presence of en-
dothelial dysfunction. So far, several
cardiovascular drugs have been shown to
improve compromised endothelial func-
tionthroughsupposedpleiotropicand/or
ancillary properties. However, it is difﬁ-
cult to highlight the direct effect on endo-
thelium against the indirect effect of the
speciﬁc drugs, such as the blood pres-
sure–lowering, lipid-lowering, or insulin
sensitivity–improving effect. Nonethe-
less, the endothelium is increasingly be-
coming a surrogate end point of the
therapeutic approach to cardiovascular
risk, as demonstrated by its inclusion
among markers of organ damage in the
latest European hypertension guidelines
(55).Althoughitispossiblethatendothe-
lial dysfunction is only a marker of car-
diovascular risk, in the clinical practice,
the development of a technique to easily
and noninvasively explore endothelial
function at a low cost will afford a reliable
index of the effectiveness of patients’ car-
diovascular therapy.
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